Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US0327973006
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000C9K8K4
AVXL
Anavex Life Sciences Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Anavex Life Sciences Corp
ISIN
US0327973006
TICKER
AVXL
MIC
XNAS
REUTERS
AVXL.OQ
BLOOMBERG
AVXL US
Do., 01.10.2026       Anavex Life Sciences
US0327973006

Law Offices of Howard G. Smith announces an investigation on behalf of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ANAVEX LIFE SCIENCES CORP. (AVXL), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABO...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Do., 01.10.2026       Anavex Life Sciences
US0327973006

Philadelphia, Pennsylvania--(Newsfile Corp. - October 1, 2026) - What is The Investigation About? Grabar Law Office is investigating whether certain officers and directors of Anavex Life Sciences Corp. (NASDAQ: AVXL) breached their fiduciary duties owed to the Company and its shareholders.Current Anavex (NASDAQ: AVXL) shareholders who have held Ana...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Do., 01.10.2026       Anavex Life Sciences
US0327973006

LOS ANGELES, Oct. 1, 2026/PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. ("Anavex" or "the Company") (NASDAQ: AVXL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulga...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Do., 01.10.2026       Anavex Life Sciences
US0327973006

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026, inclusive (“the Class Period”). If you suffered a loss on your Anavex investments, you have until...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mi., 30.09.2026       Anavex Life Sciences
US0327973006

The Law Offices of Frank R. Cruz announces an investigation of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ANAVEX LIFE SCIENCES CORP. (AVXL), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PU...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mi., 30.09.2026       Anavex Life Sciences
US0327973006

NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mi., 30.09.2026       Anavex Life Sciences
US0327973006

The DJS Law Group reminds investors of a class action lawsuit against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of AVXL duri...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mi., 30.09.2026       Anavex Life Sciences
US0327973006

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) and reminds investors of the November 30, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. T...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mi., 30.09.2026       Anavex Life Sciences
US0327973006

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Anavex Life Sciences Corp. (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026, inclusive (the "Class Period"). Anavex describes itself as "a publicly traded biopharmaceuti...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mi., 30.09.2026       Anavex Life Sciences
US0327973006

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 30.09.2026       Anavex Life Sciences
US0327973006

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Anavex Life Sciences investors unde...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Di., 29.09.2026       Anavex Life Sciences
US0327973006

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued mat...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Do., 24.09.2026       Anavex Life Sciences
US0327973006

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. T...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Do., 24.09.2026       Anavex Life Sciences
US0327973006

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that, based on the preliminary vote count provided by its proxy solicitor fol...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mi., 23.09.2026       Anavex Life Sciences
US0327973006

New York, New York--(Newsfile Corp. - September 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Di., 22.09.2026       Anavex Life Sciences
US0327973006

NEW YORK, Sept. 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued mat...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
So., 20.09.2026       Anavex Life Sciences
US0327973006

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the investing public. So What: If you purchased Anavex securi...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mo., 14.09.2026       Anavex Life Sciences
US0327973006

ISS Recognizes There is No Case for Change...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Di., 08.09.2026       Anavex Life Sciences
US0327973006

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced it will host a conference call at 4:00 PM ET on Wednesday, Sep...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Di., 25.08.2026       Anavex Life Sciences
US0327973006

Clinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 17.08.2026       Anavex Life Sciences
US0327973006

Launches VoteAnavex.com to Provide Additional Information on Anavex’s Director Nominees and How to Vote at the Annual Meeting of Stockholders...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Do., 30.07.2026       Anavex Life Sciences
US0327973006

Establishing Disciplined, Data-Driven Strategy with Focus on FDA Engagement for Alzheimer’s Disease Establishing Disciplined, Data-Driven Strategy with Focus on FDA Engagement for Alzheimer’s Disease...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Fr., 22.05.2026       Anavex Life Sciences
US0327973006

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the “Notice”) from the Listing...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Anavex Life Sciences
US0327973006

Findings underpin the scientific rationale for Anavex’s targeted autophagy approach with orally administered blarcamesine...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Anavex Life Sciences
US0327973006

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, a...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Anavex Life Sciences
US0327973006

Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       Anavex Life Sciences
US0327973006

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mi., 25.03.2026       Anavex Life Sciences
US0327973006

NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, a...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mo., 23.03.2026       Anavex Life Sciences
US0327973006

New data show brain-volume preservation correlates with patient outcomes...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Fr., 20.03.2026       Anavex Life Sciences
US0327973006

Findings underpin potential of Anavex’ lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy restoration Findings underpin potential of Anavex’ lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy restoration...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Anavex Life Sciences
US0327973006

New data show that blarcamesine completely rescued impaired motor function...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Di., 03.03.2026       Anavex Life Sciences
US0327973006

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, a...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mi., 25.02.2026       Anavex Life Sciences
US0327973006

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, an...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mo., 23.02.2026       Anavex Life Sciences
US0327973006

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, an...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mo., 09.02.2026       Anavex Life Sciences
US0327973006

Company to host a webcast today at 8:30 am Eastern Time...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Di., 03.02.2026       Anavex Life Sciences
US0327973006

Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ET Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ET...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Di., 13.01.2026       Anavex Life Sciences
US0327973006

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new European initiative designed to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer’s disease (AD) across rea...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Fr., 09.01.2026       Anavex Life Sciences
US0327973006

NEWTOWN, Pa., Jan. 8, 2026 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Anavex Life Sciences Corp. ("Anavex") (NASDAQ: AVXL), resulting from allegations of providing potentially misleading business information to the investing public....
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Do., 08.01.2026       Anavex Life Sciences
US0327973006

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Do., 08.01.2026       Anavex Life Sciences
US0327973006

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, an...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Di., 06.01.2026       Anavex Life Sciences
US0327973006

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, an...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Do., 01.01.2026       Anavex Life Sciences
US0327973006

NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Anavex Life Sciences Corp.  ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Do., 18.12.2025       Anavex Life Sciences
US0327973006

NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, an...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       Anavex Life Sciences
US0327973006

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, an...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Do., 11.12.2025       Anavex Life Sciences
US0327973006

NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Anavex Life Sciences Corp.  ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Do., 04.12.2025       Anavex Life Sciences
US0327973006

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or faile...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mi., 26.11.2025       Anavex Life Sciences
US0327973006

One Oral Late Breaking Communication and Two Poster Presentations One Oral Late Breaking Communication and Two Poster Presentations...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Di., 25.11.2025       Anavex Life Sciences
US0327973006

Company to host a webcast today at 8:30 a.m. Eastern Time...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mi., 19.11.2025       Anavex Life Sciences
US0327973006

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, an...
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink
Mi., 19.11.2025       Anavex Life Sciences
US0327973006

NEW YORK, Nov. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Anavex Life Sciences Corp.  ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Anavex Life Sciences
Charts & Research Termsheets Terminal
Permalink